Artivion, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- James Mackin
- Full Time Employees
- 1,200
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 1655 Roberts Blvd NW Kennesaw GA United States of America 30144
- IPO Date
- Feb 12, 1993
- CIK
- 0000784199
- Website
- artivion.com
- Similar Companies
- Business
- Artivion, Inc. (NYSE: AORT; formerly CryoLife, Inc.) manufactures, processes and distributes medical devices and implantable tissues for cardiac and vascular surgical procedures, with a focus on the treatment of aortic diseases; core products and services include aortic stent grafts such as NEXUS®, NEXUS DUO™, NEXUS TRE™, E-vita® Open Neo, Neo EDE™, E-xtra Design MultiBranch, E-nside™ TAAA, Artivex™ and abdominal/peripheral aorta stent grafts; On-X® mechanical heart valves and surgical products; surgical sealants including BioGlue®; cryopreserved human tissue allografts such as CryoVein®, CryoArtery®, CryoPatch® SG, CryoGraft® and PhotoFix®; and ancillary solutions like CarbonAid®, E-wire guidewires and E-xpand balloon catheters. Founded in 1984 and headquartered in Kennesaw, Georgia, the company operates globally with manufacturing, sales and distribution in the United States, Europe, Asia Pacific, Latin America and other regions, serving cardiac, vascular and thoracic surgeons, hospitals and healthcare facilities. Recent developments include amended funding and purchase option terms with Endospan Ltd. in 2024 for up to $25 million in additional loans and a reduced upfront acquisition price to $175 million for the NEXUS Stent Graft System pending U.S. FDA approval; $350 million in credit facilities from Ares Management in January 2024 comprising a $190 million term loan, $100 million delayed draw term loan and $60 million revolver; the exchange of $99.5 million in 4.25% convertible senior notes due 2025 for common stock in May 2025; FDA IDE approval for the ARTIZEN pivotal trial of the Arcevo LSA device; positive clinical data from AMDS PERSEVERE and PROTECT trials presented in 2025 supporting premarket approval for acute aortic dissection treatment; and launches including AMDS with U.S. PMA approval in late 2024 and ongoing expansions in On-X valves, stent grafts and geographic markets like Asia Pacific and Latin America, driving reported revenue growth and raised 2024-2025 guidance.
GraniteShares Announces Weekly Distributions for its YieldBOOST ETFs
GraniteShares Announces Weekly Distributions for its YieldBOOST ETFs: COYY, TSYY, NVYY, XBTY, AMYY, TQQY, AZYY, YSPY, MTYY, PLYY, HOYY, SMYY, BBYY, FBYY, IOYY, MAAY, NUGY, SEMY, QBY, RGYY, HMYY, RTYY, MUYY, TMYY, CWY, CRY and 20+ Others
GraniteShares Expands YieldBOOST(TM) Lineup with Launch of CRY and XEY ETFs
Artivion, Inc. (AORT) Q2 2024 Earnings Call Transcript
Artivion (AORT) Surpasses Q2 Earnings and Revenue Estimates
Artivion Reports Second Quarter 2024 Financial Results
Artivion to Participate in Upcoming Investor Conferences
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2024 Financial Results
Artivion Amends Agreements with Endospan
Data-Driven Growth Fuels More Upside For Overlooked Artivion
Artivion Obtains $350 Million in Senior Secured Credit Facilities
Artivion Announces FDA PMA Approval of PerClot and Transfer of PMA to Baxter
A Trio of Low Price-Sales Ratio Stocks
Wall Street Analysts Think CryoLife (CRY) Could Surge 51%: Read This Before Placing a Bet
CryoLife, Inc. (CRY) CEO J. Patrick Mackin on Q3 2021 Results - Earnings Call Transcript
Recap: Cryolife Q3 Earnings
Anthony Semedo Joins CryoLife Board of Directors
CryoLife to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
CryoLife, Inc. (CRY) CEO Pat Mackin on Q2 2021 Results - Earnings Call Transcript
CryoLife (CRY) Reports Q2 Loss, Tops Revenue Estimates